You are here
Articles
Posted on Tuesday, July 3, 2012 - 4:14pm
New Data Confirm Safety of Stopping Imatinib in Leukemia
IMNG Medical Media. 2012 Jun 26, S Freeman
Posted on Monday, June 25, 2012 - 7:13pm
Ho-Young Yhim, Na-Ri Lee, Eun-Kee Song, Chang-Yeol Yim, So Yeon Jeon, Seunghwan Shin, Jeong-A Kim, Hee Sun Kim, Eun Hae Cho, Jae-Yong Kwak
Division of Hematology/Oncology, Department of Internal Medicine, Republic of...
Posted on Monday, June 11, 2012 - 3:46pm
PACE: Robust and Durable Antileukemic Responses With Ponatinib in Patients With Heavily Pretreated, Refractory CML or Ph+ ALL
Posting Date: June 06, 2012
Updated analysis of PACE: single-arm phase II trial[1]
Summary of...
Posted on Saturday, May 26, 2012 - 7:28pm
Critical Reviews in Oncology/Hematology
Javier Pinilla-Ibarz, Ian Flinn -
published online 09 April 2012.
Posted on Thursday, May 10, 2012 - 12:56pm
Inhibition of CXCR4 in CML cells disrupts their interaction with the bone marrow microenvironment and sensitizes them to nilotinib
E Weisberg1,5, A K Azab1,5, P W Manley2, A L Kung3, A L Christie3, R Bronson4, I M...
Posted on Thursday, May 3, 2012 - 11:49am
My Approach to Chronic Myeloid Leukemia
Interview by L Scott Zoeller. 2012 Apr 3, Tim Hughes, MD
Posted on Thursday, May 3, 2012 - 11:41am
Stopping Dasatinib and Nilotinib Explored in Chronic Myeloid Leukemia
Elsevier Global Medical News. 2011 Jun 30, S Freeman
Posted on Sunday, April 15, 2012 - 8:08pm
In the circumstances we feel we have done all we can and that an appeal is not a
positive option for us. We feel our focus must now shift to ensuring that applications to the Cancer Drugs Fund are successful on every...
Posted on Thursday, March 29, 2012 - 1:27am
<span id="welcome_story">
<a style="float: right; padding-left: 8px;" href="...
Posted on Friday, March 23, 2012 - 10:24am
In the circumstances we feel we have done all we can and that an appeal is not a positive option for us.
Posted on Wednesday, March 7, 2012 - 12:57pm
Leukemia 26, 490-498 (March 2012) | doi:10.1038/leu.2011.231
Posted on Wednesday, February 22, 2012 - 2:10pm
Clinical Care Options Oncology
Chronic Myeloid Leukaemia Treatment in Evolution: Recent Advances in Therapy. Moshe Talpaz, MD.
Posted on Sunday, February 5, 2012 - 12:41pm
Abstract
The outcome of chronic myeloid leukemia (CML) has been profoundly changed by the introduction of tyrosine kinase inhibitors into therapy, but the prognosis of patients with CML is still...
Posted on Sunday, February 5, 2012 - 11:40am
Elsevier Global Medical News. 2011 Jun 23, S Freeman
- ‹ previous
- 15 of 29
- next ›